Download PDF
Der Klinikarzt 2017; 46(03): 99-103
DOI: 10.1055/s-0043-105179
Serie
© Georg Thieme Verlag Stuttgart · New York

Aktuelle Datenlage zur elektrischen Kardioversion bei Vorhofflimmern unter NOAKs

Ein ÜberblickCurrent data of electrical cardioversion in atrial fibrillation under NOACs – An overview
Andreas Goette
1   St. Vincenz-Krankenhaus, Medizinische Klinik II, Paderborn
2   Arbeitsgruppe: Molekulare Elektrophysiologie, Universitätsklinikum Magdeburg
,
Matthias Hammwöhner
1   St. Vincenz-Krankenhaus, Medizinische Klinik II, Paderborn
› Author Affiliations
Further Information

Publication History

Publication Date:
04 April 2017 (online)

Also available at
    Permissions and Reprints

Die Kardioversion von Vorhofflimmern gehört zur klinischen Routine. Obwohl dieses Verfahren in vielen tausend Fällen pro Jahr allein in Deutschland durchgeführt wird, war die wissenschaftliche Datenlage aus prospektiven, randomisierten Studien bislang limitiert. Durch Einführung der nicht- Vitamin-K-Antagonist oralen Antikoagulanzien (NOAK) gibt es nun große prospektiven Studien zur Kardioversion von Vorhofflimmern. In diesen Studien (ENSURE AF, XVeRT) wurden die elektrische und pharamkologische Kardioversion von Vorhofflimmern unter NOAK untersucht und zudem die TEE-gesteuerte Kardioversion mit einem konservativen Ansatz verglichen. Es konnte hierdurch gezeigt werden, dass die Behandlung mit NOAK (Edoxaban und Rivaroxan) effektiv und sicher bei Patienten ist, die wegen Vorhofflimmern kardiovertiert werden müssen. Der vorliegende Artikel fasst die wesentlichen, bisher verfügbaren Daten zur Kardioversion von Vorhofflimmern zusammen.

Cardioversion of atrial fibrillation is of major importance in clinical practice. However, data from prospective and randomized trials were limited. With the introduction of non-vitamin K antogonist oral anticoagulans (NOAC) for therapy of patients with atrial fibrillation, the largest prospective trials ever on cardioversion have been published. The ENSURE AF trial and the XVeRT study could show that cardioversion of atrial fibrillation is safe and effective in patients treated with NOAC. In addition, the two studies helped to examine the impact of transesophageal echocardiography in patients undergoing cardioversion. This review summarizes the most recent and relevant information in this important clinical field.

Key words

Anticoagulation - echocardiography - cardioversion - NOAC - stroke - atrial fibrillation
 

  • Literatur

  • 1 Lown B, Bey SK, Perloth MG, Abe T. Cardioversion of Ectopic Tachycardias. Am J Med Sci 1963; 246: 257-264
    CrossrefPubMedGoogle Scholar
  • 2 Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691-704
    CrossrefPubMedGoogle Scholar
  • 3 Carlsson J, Tebbe U, Rox J et al Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte. Am J Cardiol 1996; 78: 1380-1384
    CrossrefPubMedGoogle Scholar
  • 4 Palomäki A, Mustonen P, Hartikainen JE et al Strokes after cardioversion of atrial fibrillation--The FibStroke study. Int J Cardiol 2016; 203: 269-273
    CrossrefPubMedGoogle Scholar
  • 5 Goette A, Kalman JM, Aguinaga L et al EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016; 18: 1455-1490
    CrossrefPubMedGoogle Scholar
  • 6 Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C, Goette A. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol 2013; 718: 114-123
    CrossrefPubMedGoogle Scholar
  • 7 Klein AL, Grimm RA, Murray RD et al Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420
    CrossrefPubMedGoogle Scholar
  • 8 Kirchhof P, Benussi S, Kotecha D et al 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962
    CrossrefPubMedGoogle Scholar
  • 9 Renda G, Ricci F, De CR. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. Am J Med. 2016 [Epub ahead of print]
    PubMedGoogle Scholar
  • 10 Flaker G, Lopes RD, Hylek E et al Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 64: 1541-1550
    CrossrefPubMedGoogle Scholar
  • 11 Nagarakanti R, Ezekowitz MD, Oldgren J et al Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136
    CrossrefPubMedGoogle Scholar
  • 12 Piccini JP, Stevens SR, Lokhnygina Y et al Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006
    CrossrefPubMedGoogle Scholar
  • 13 Plitt A, Ezekowitz MD, De CR, Nordio F, Peterson N, Giugliano RP. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 2016; 39: 345-346
    CrossrefPubMedGoogle Scholar
  • 14 Cappato R, Ezekowitz MD, Klein AL et al Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35: 3346-3355
    CrossrefPubMedGoogle Scholar
  • 15 Goette A, Merino JL, Ezekowitz MD et al Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016; 388: 1995-2003
    CrossrefPubMedGoogle Scholar
  • 16 Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J 2015; 169: 597-604
    CrossrefPubMedGoogle Scholar
  • 17 Goette A, Hammwöhner M. How important it is for therapy adherence to be once a day?. Eur Heart J 2016; 18 (Supplement I) I7-I12
    PubMedGoogle Scholar